Response to anti-angiogenesis: An ever changing feature

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Aims: Anti-angiogenic drugs have gained international approval for the therapy of advanced breast, lung, colo-rectal, kidney and central nervous system cancer. However, the clinical benefit associated with the use of these drugs has been so far limited. Methods: This review discuss the possible rational developments of a new generation anti-angiogenic drugs. Conclusion: Since most of the biological and clinical activity of the currently available generation of anti-angiogenic drugs targets VEGF and its related pathways, it seems relevant to (1) better understand mechanisms of resistance and/or escape from anti-VEGF and (2) identify and validate vascular targets complementary to anti-VEGF.

Original languageEnglish
JournalBreast
Volume20
Issue numberSUPPL. 3
DOIs
Publication statusPublished - Oct 2011

Fingerprint

Angiogenesis Inhibitors
Vascular Endothelial Growth Factor A
Blood Vessels
Breast
Central Nervous System
Kidney
Lung
Pharmaceutical Preparations
Neoplasms
Therapeutics

Keywords

  • Angiogenesis
  • Anti-angiogenesis
  • Anti-VEGF
  • Endothelial cells
  • VEGF

ASJC Scopus subject areas

  • Surgery

Cite this

Response to anti-angiogenesis : An ever changing feature. / Bertolini, Francesco.

In: Breast, Vol. 20, No. SUPPL. 3, 10.2011.

Research output: Contribution to journalArticle

@article{b42138ec789446188a9238f96a5377c0,
title = "Response to anti-angiogenesis: An ever changing feature",
abstract = "Aims: Anti-angiogenic drugs have gained international approval for the therapy of advanced breast, lung, colo-rectal, kidney and central nervous system cancer. However, the clinical benefit associated with the use of these drugs has been so far limited. Methods: This review discuss the possible rational developments of a new generation anti-angiogenic drugs. Conclusion: Since most of the biological and clinical activity of the currently available generation of anti-angiogenic drugs targets VEGF and its related pathways, it seems relevant to (1) better understand mechanisms of resistance and/or escape from anti-VEGF and (2) identify and validate vascular targets complementary to anti-VEGF.",
keywords = "Angiogenesis, Anti-angiogenesis, Anti-VEGF, Endothelial cells, VEGF",
author = "Francesco Bertolini",
year = "2011",
month = "10",
doi = "10.1016/S0960-9776(11)70296-X",
language = "English",
volume = "20",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Response to anti-angiogenesis

T2 - An ever changing feature

AU - Bertolini, Francesco

PY - 2011/10

Y1 - 2011/10

N2 - Aims: Anti-angiogenic drugs have gained international approval for the therapy of advanced breast, lung, colo-rectal, kidney and central nervous system cancer. However, the clinical benefit associated with the use of these drugs has been so far limited. Methods: This review discuss the possible rational developments of a new generation anti-angiogenic drugs. Conclusion: Since most of the biological and clinical activity of the currently available generation of anti-angiogenic drugs targets VEGF and its related pathways, it seems relevant to (1) better understand mechanisms of resistance and/or escape from anti-VEGF and (2) identify and validate vascular targets complementary to anti-VEGF.

AB - Aims: Anti-angiogenic drugs have gained international approval for the therapy of advanced breast, lung, colo-rectal, kidney and central nervous system cancer. However, the clinical benefit associated with the use of these drugs has been so far limited. Methods: This review discuss the possible rational developments of a new generation anti-angiogenic drugs. Conclusion: Since most of the biological and clinical activity of the currently available generation of anti-angiogenic drugs targets VEGF and its related pathways, it seems relevant to (1) better understand mechanisms of resistance and/or escape from anti-VEGF and (2) identify and validate vascular targets complementary to anti-VEGF.

KW - Angiogenesis

KW - Anti-angiogenesis

KW - Anti-VEGF

KW - Endothelial cells

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=80054865022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054865022&partnerID=8YFLogxK

U2 - 10.1016/S0960-9776(11)70296-X

DO - 10.1016/S0960-9776(11)70296-X

M3 - Article

C2 - 22015295

AN - SCOPUS:80054865022

VL - 20

JO - Breast

JF - Breast

SN - 0960-9776

IS - SUPPL. 3

ER -